← All indications
Hepatic Insufficiency
Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.
Subtype terms (1)
More specific conditions that are subtypes of Hepatic Insufficiency in the MeSH hierarchy.
- Liver Failure
70 drugs (46 approved, 24 experimental)
Drugs by status
Phase 4 trials (2)
Phase 2 trials (1)
Phase 1 trials (65)
- diclofenac
- dotinurad
- azacitidine
- abemaciclib
- acalabrutinib
- axitinib
- alisporivir
- Mavorixafor
- ridaforolimus
- urea
- darolutamide
- nerandomilast
- bi 425809
- avenciguat
- dabigatran
- odanacatib
- otenabant
- tofacitinib
- suvorexant
- dulaglutide
- elbasvir
- empagliflozin
- entrectinib
- evacetrapib
- nesbuvir
- nintedanib
- ritonavir
- img-7289
- baricitinib
- etomidate
- +35 more
Organizations
Organization Involved with Phase 4 Indications (13)
- Indivior Inc.
- Boehringer Ingelheim
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
- Medical University of Warsaw
- Menoufia University
- Postgraduate Institute of Medical Education and Research
- Orlando Clinical Research Center
- Clinical Pharmacology of Miami
- American Research Corporation (ARC)
- Government of Egypt
- People's Liberation Army of China
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (19)
- Merck
- Grifols
- Mylan
- CardiOx Corporation
- Exalenz Bioscience LTD.
- Madaus Inc
- University of Pittsburgh
- Korea University
- Pavol Jozef Safarik University
- University of Michigan
- Fudan University
- Institute of Liver and Biliary Sciences, India
- Medical University of South Carolina
- Asian Institute of Gastroenterology
- Dominican Santa Cruz Hospital
- University of Paris
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
- Pharmbio Korea
- Assistance Publique - Hôpitaux de Paris
Organization Involved with Phase 2 Indications (23)
- Alfact Innovation
- Betta Pharmaceuticals Co.,Ltd.
- FGK Clinical Research GmbH
- Ocera Therapeutics
- Rheacell GmbH & Co. KG
- Promethera Biosciences
- University of London
- Kyoto University
- University of Heidelberg
- University of Nottingham
- University of Padova
- Virginia Commonwealth University
- Tianjin University of Traditional Chinese Medicine
- University of Copenhagen
- All India Institute of Medical Sciences
- Istituto Clinico Humanitas - Rozzano (MI), Italy
- Conatus Pharmaceuticals
- Louisiana State University
- Sun Yat-Sen University
- TICEBA GmbH
- IQVIA
- Tianjin Weikai Bioeng., Ltd.
- Akaza Bioscience Ltd
Organization Involved with Phase 1 Indications (41)
- Acorda Therapeutics
- Javelin Pharmaceuticals
- ViroPharma
- Bristol-Myers Squibb
- Vertex
- Debiopharm
- Roche
- Astellas
- AstraZeneca
- Medivation
- Eli Lilly
- Genentech
- Pfizer
- Wyeth
- Novartis
- Ariad Pharmaceuticals
- Bayer
- BeOne Medicines
- Biotie Therapies
- FibroGen
- Mochida Pharmaceutical Company, Ltd.
- Neurocrine Biosciences
- Tobira Therapeutics, Inc.
- Fuji Yakuhin Co., Ltd.
- PharmaMar
- Puma Biotechnology, Inc.
- Steminent Biotherapeutics Inc.
- Hospital Clinic of Barcelona
- Indiana University
- University of Miami
- +11 more
Organization Involved with Other Experimental Indications (22)
- Huazhong University of Science and Technology
- Aarhus University
- Eastern Hepatobiliary Surgery Hospital
- Guangxi Medical University
- Jilin University
- Shanghai University of Traditional Chinese Medicine
- Shenzhen Third People's Hospital
- University of Leipzig
- Capital Medical University
- Columbia University
- Hunan University of Traditional Chinese Medicine
- Xiamen University
- Southern Medical University
- Government of China
- Henan Medical University
- Hepatobiliary Disease Hospital of Jilin Province, Jilin, China
- Shenzhen University
- China Medical University
- Hubei University of Chinese Medicine
- Fuzhou Infectious Hospital
- Hangzhou Xixi hospital
- Axcella Health Inc.